It looks like Nestle (NSRGY) is paying a healthy 19.8 times 2012 EBITDA for Pfizer’s (PFE) nutrition business.  That is a pretty high multiple but Nestle is betting on cost synergies, and high growth prospects from the emerging markets that the business operates in.  Nestle has and also produces a lot of cash so this...Read More

I absolutely love this deal for both companies as Pfizer is monetizing some of their faster growing assets which haven’t been reflected in the stock’s valuation, and Nestle is acquiring a company that fits into their core business model.  I’d need to know more details about the division to provide more commentary on valuation but...Read More